Overview

R115777 in Treating Patients With Relapsed Small Cell Lung Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborator:
National Cancer Institute (NCI)
Treatments:
Tipifarnib